Paula Debroy1, Jordan E Lake1, Carlee Moser2, Maxine Olefsky2, Kristine M Erlandson3, Ann Scherzinger3, James H Stein4, Judith S Currier5, Todd T Brown6, Grace A McComsey7. 1. University of Texas Health Science Center at Houston, Houston, Texas, USA. 2. Harvard University, Boston, Massachusetts, USA. 3. University of Colorado, Aurora, Colorado, USA. 4. University of Wisconsin, Madison, Wisconsin, USA. 5. University of California, Los Angeles, California, USA. 6. Johns Hopkins University, Baltimore, Maryland, USA. 7. University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio, USA.
Abstract
BACKGROUND: Adipose tissue (AT) alterations are common in people living with human immunodeficiency virus (PLWH). Decreases in AT density suggest disrupted adipocyte function/hypertrophy. We assessed changes in AT density after antiretroviral therapy (ART) initiation and associations with immunometabolic parameters. METHODS: In a prospective randomized clinical trial of ART initiation, L4-L5 abdominal CT scans measured subcutaneous AT (SAT) and visceral AT (VAT) area and density in treatment-naive PLWH randomized to tenofovir-emtricitabine plus ritonavir-boosted atazanavir, ritonavir-boosted darunavir, or raltegravir. Linear regression models compared week 0 and week 96 levels, and 96-week changes, in SAT and VAT density (in Hounsfield units [HU]). Spearman correlations assessed relationships between AT density and immunometabolic parameters. RESULTS: Of the 228 participants, 89% were male and 44% were white non-Hispanic. Median age was 36 years, baseline HIV-1 RNA was 4.6 log10 copies/mL, and CD4+ T-cell count was 344 cells/μL. Over 96 weeks, SAT and VAT HU decreased significantly in all arms. Less dense week 96 SAT and VAT density correlated with higher high-density lipoprotein (HDL) cholesterol and adiponectin (r = 0.19-0.30) levels and lower interleukin 6, non-HDL cholesterol, triglyceride, leptin, and homeostatic model assessment of insulin resistance (r = -0.23 to -0.68) levels at week 96 after adjusting for baseline CD4+ T-cell count, HIV-1 RNA, and baseline AT area. CONCLUSIONS: Following virologic suppression, lower SAT and VAT density was associated with greater plasma measures of systemic inflammation, lipid disturbances, and insulin resistance independent of AT area, suggesting that changes in AT density with ART may lead to adverse health outcomes independent of AT quantity. CLINICAL TRIALS REGISTRATION: NCT00851799.
RCT Entities:
BACKGROUND: Adipose tissue (AT) alterations are common in people living with human immunodeficiency virus (PLWH). Decreases in AT density suggest disrupted adipocyte function/hypertrophy. We assessed changes in AT density after antiretroviral therapy (ART) initiation and associations with immunometabolic parameters. METHODS: In a prospective randomized clinical trial of ART initiation, L4-L5 abdominal CT scans measured subcutaneous AT (SAT) and visceral AT (VAT) area and density in treatment-naive PLWH randomized to tenofovir-emtricitabine plus ritonavir-boosted atazanavir, ritonavir-boosted darunavir, or raltegravir. Linear regression models compared week 0 and week 96 levels, and 96-week changes, in SAT and VAT density (in Hounsfield units [HU]). Spearman correlations assessed relationships between AT density and immunometabolic parameters. RESULTS: Of the 228 participants, 89% were male and 44% were white non-Hispanic. Median age was 36 years, baseline HIV-1 RNA was 4.6 log10 copies/mL, and CD4+ T-cell count was 344 cells/μL. Over 96 weeks, SAT and VAT HU decreased significantly in all arms. Less dense week 96 SAT and VAT density correlated with higher high-density lipoprotein (HDL) cholesterol and adiponectin (r = 0.19-0.30) levels and lower interleukin 6, non-HDL cholesterol, triglyceride, leptin, and homeostatic model assessment of insulin resistance (r = -0.23 to -0.68) levels at week 96 after adjusting for baseline CD4+ T-cell count, HIV-1 RNA, and baseline AT area. CONCLUSIONS: Following virologic suppression, lower SAT and VAT density was associated with greater plasma measures of systemic inflammation, lipid disturbances, and insulin resistance independent of AT area, suggesting that changes in AT density with ART may lead to adverse health outcomes independent of AT quantity. CLINICAL TRIALS REGISTRATION: NCT00851799.
Authors: Jamison Norwood; Megan Turner; Carmen Bofill; Peter Rebeiro; Bryan Shepherd; Sally Bebawy; Todd Hulgan; Stephen Raffanti; David W Haas; Timothy R Sterling; John R Koethe Journal: J Acquir Immune Defic Syndr Date: 2017-12-15 Impact factor: 3.731
Authors: Jordan E Lake; David Wohl; Rebecca Scherzer; Carl Grunfeld; Phyllis C Tien; Stephen Sidney; Judith S Currier Journal: AIDS Care Date: 2011-06-24
Authors: Jordan E Lake; Carlee Moser; Liz Johnston; Clara Magyar; Scott D Nelson; Kristine M Erlandson; Todd T Brown; Grace A McComsey Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Marta Giralt; Pere Domingo; Jordi P Guallar; M Luísa Rodriguez de la Concepción; Marta Alegre; Joan C Domingo; Francesc Villarroya Journal: Antivir Ther Date: 2006
Authors: Magdalena Pasarica; Barbara Gowronska-Kozak; David Burk; Isabel Remedios; David Hymel; Jeff Gimble; Eric Ravussin; George A Bray; Steven R Smith Journal: J Clin Endocrinol Metab Date: 2009-10-16 Impact factor: 5.958
Authors: Yourka D Tchoukalova; Christina Koutsari; Maksym V Karpyak; Susanne B Votruba; Eliana Wendland; Michael D Jensen Journal: Am J Clin Nutr Date: 2008-01 Impact factor: 7.045
Authors: Samuel S Bailin; Curtis L Gabriel; Run Fan; Fei Ye; Sangeeta Nair; James G Terry; John J Carr; Heidi Silver; Celestine N Wanjalla; Mona Mashayekhi; Morgan Lima; Beverly Woodward; LaToya Hannah; Hubaida Fuseini; Jane F Ferguson; Jonathan A Kropski; John R Koethe Journal: J Acquir Immune Defic Syndr Date: 2022-06-01 Impact factor: 3.771
Authors: Curtis L Gabriel; Fei Ye; Run Fan; Sangeeta Nair; James G Terry; John Jeffrey Carr; Heidi Silver; Paxton Baker; LaToya Hannah; Celestine Wanjalla; Mona Mashayekhi; Sam Bailin; Morgan Lima; Beverly Woodward; Manhal Izzy; Jane F Ferguson; John R Koethe Journal: Hepatol Commun Date: 2021-02-27
Authors: John R Koethe; Carlee Moser; Todd T Brown; James H Stein; Theodoros Kelesidis; Michael Dube; Judith Currier; Grace A McComsey Journal: Clin Infect Dis Date: 2022-03-09 Impact factor: 20.999
Authors: Arianna Kousari; Carlee Moser; Maxine Olefsky; Todd T Brown; Judith S Currier; Grace A McComsey; Ann Scherzinger; James H Stein; Jordan E Lake; Kristine M Erlandson Journal: J Acquir Immune Defic Syndr Date: 2021-12-01 Impact factor: 3.771